Abstracts tagged "Validity and outcome measures"

Abstract Number: 1412 • 2016 ACR/ARHP Annual Meeting
Validation of the Danish Version of the Stanford Health Assessment Questionnaire Disability Index and Determination of the Minimal Clinically Important Difference in a Cohort of Rheumatoid Arthritis Patients Using the Rasch Measurement Model
Lykke Midtbøll Ørnbjerg¹, Karl Bang Christensen², Alan Tennant³ and Merete Lund Hetland⁴, ¹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, ²Department of Biostatistics, University of Copenhagen, Copenhagen, Denmark, ³Swiss Paraplegic Research, Nottwil, Switzerland, ⁴Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Denmark, Copenhagen, Denmark
Background/Purpose: The Stanford Health Assessment Questionnaire Disability Index (HAQ-DI) is a widely used patient reported outcome for functional disability in RA. Minimal clinically important differences…
Abstract Number: 1081 • 2015 ACR/ARHP Annual Meeting
Administration of Patient Reported Outcome Measurement Information System (PROMIS) Instruments By Computer Adaptive Testing in Patients with Systemic Vasculitis
Gunnar Tomasson¹, John T. Farrar², David Cuthbertson³, Carol McAlear⁴, Susan Asdown⁵, Don Gebhart⁶, Georgia Lanier⁷, Nataliya Milman⁸, Jacqueline Peck⁹, Joanna Robson¹⁰, Simon Carette¹¹, Gary S. Hoffman¹², Nader A. Khalidi¹³, Curry L. Koening¹⁴, Carol A. Langford¹², Larry W. Moreland¹⁵, Paul A. Monach¹⁶, Christian Pagnoux¹¹, Ulrich Specks¹⁷, Antoine G. Sreih¹⁸, Steven R. Ytterberg¹⁹ and Peter A. Merkel⁴, ¹Dept of Public Health Sciences, University of Iceland, Reykiavik, Iceland, ²Universitiy of Pennsylvania, Philadelphia, PA, ³Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, ⁴Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁵NONE, Branbury, United Kingdom, ⁶NONE, Columbus, OH, ⁷NONE, Framingham, MA, ⁸Division of Rheumatology, University of Ottawa, Ottawa, ON, Canada, ⁹Oxford University, Oxford, United Kingdom, ¹⁰Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, University of Oxford, Oxford, United Kingdom, ¹¹Mount Sinai Hospital, Toronto, ON, Canada, ¹²Rheumatology, Cleveland Clinic, Cleveland, OH, ¹³McMaster University, Hamilton, ON, Canada, ¹⁴Division of rheumatology, George E. Wahlen Department of Veterans Affairs Medical Center Salt Lake City and University of Utah, University of Utah School of Medicine, Salt Lake City, UT, ¹⁵Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ¹⁶Rheumatology, Boston University School of Medicine, Boston, MA, ¹⁷Division of Pulmonary and Critical Care Medicine, Mayo Clinic College of Medicine, Rochester, MN, ¹⁸Department of Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹⁹Rheumatology Division, Mayo Clinic, Rochester, MN
Background/Purpose: Currently-used outcome measures in vasculitis insufficiently capture the life impact of systemic vasculitis from patients' perspectives. The Patient Reported Outcome Measurement Information System…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].